As these anti-apoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by the inhibitor of integrin-linked kinase QLT0267, they suggested that the upregulation of CXCR4 by imatinib promotes migration of chronic myelogenous leukemia (CML) cells to bone marrow stroma, causing G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells [89]. Here, ILK is linked to chronic myelogenous leukemia, BCR-ABL1 positive.